close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ADMA Biologics Inc - Common Stock (NQ:ADMA)

10.43 +0.12 (+1.12%)
Delayed Quote Updated: 1:32 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ADMA Biologics Inc - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
News headline image
Bragar Eagel & Squire, P.C. Is Investigating ADMA Biologics, Napco, and L&W and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ADMA BIOLOGICS ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Biologics Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade ↗
Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January. 
Via Investor's Business Daily
News headline image
Key Takeaways From ADMA Biologics Analyst Ratings ↗
 
Via Benzinga
News headline image
This Is What Whales Are Betting On ADMA Biologics ↗
 
Via Benzinga
News headline image
IBD 50's Top Stock, ADMA Biologics, Crashes After Auditor Unexpectedly Resigns ↗
The company reiterated its outlook for 2024 and 2025. 
Via Investor's Business Daily
News headline image
Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits ↗
Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer. 
Via Investor's Business Daily
News headline image
CVS Has 'Real Value,' Jim Cramer Says: Micron Had An 'Amazing' Quarter ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Exploring high growth characteristics of ADMA BIOLOGICS INC (NASDAQ:ADMA). ↗
Why ADMA BIOLOGICS INC (NASDAQ:ADMA) qualifies as a high growth stock. 
Via Chartmill
News headline image
Looking for growth without the hefty price tag? Consider NASDAQ:ADMA. ↗
Looking for growth without the hefty price tag? Consider NASDAQ:ADMA. 
Via Chartmill
News headline image
In-Depth Examination Of 4 Analyst Recommendations For ADMA Biologics ↗
 
Via Benzinga
News headline image
Assessing ADMA Biologics: Insights From 4 Financial Analysts ↗
 
Via Benzinga
News headline image
ADMA Biologics Set to Join S&P SmallCap 600 Index
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
What's Going On With ADMA Biologics Stock Monday? ↗
ADMA Biologics shares are moving higher after it was announced that the company will join the S&P SmallCap 600. 
Via Benzinga
Topics Stocks
News headline image
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark ↗
Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86. 
Via Investor's Business Daily
News headline image
'This Is A Very Speculative Situation,' Jim Cramer On ADMA Biologics ↗
"Mad Money" host Jim Cramer said, "Any time there's immunity-compromised patients, there's some big money down the road." 
Via Benzinga
News headline image
Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers ↗
Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers. 
Via Investor's Business Daily
News headline image
Biohaven Stock Earns Relative Strength Rating Upgrade ↗
Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91. 
Via Investor's Business Daily
News headline image
SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating ↗
A Relative Strength Rating upgrade for SpringWorks Therapeutics shows improving technical performance. 
Via Investor's Business Daily
News headline image
Immunome Stock Sees RS Rating Jump To 91 ↗
Immunome stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 88 to 91. 
Via Investor's Business Daily
News headline image
PTC Therapeutics Stock Earns RS Rating Upgrade To 83 ↗
The Relative Strength (RS) Rating for PTC Therapeutics stock climbed into a new percentile Monday, with a rise from 80 to 83. 
Via Investor's Business Daily
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
ADMA Biologics Announces Partial Paydown of Revolving Credit Facility
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
Lumen Tech & Upstart Are Among Top 7 Mid Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio? ↗
Lumen, Upstart, ADMA, Sweetgreen, Veracyte, Clear Secure, and Core Scientific were best performers last week. Did you invest in them? 
Via Benzinga
News headline image
Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
ADMA Stock Earnings: ADMA Biologics Beats EPS, Beats Revenue for Q2 2024 ↗
ADMA stock results show that ADMA Biologics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
ADMA Biologics Announces Second Quarter 2024 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.